<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput xmlns:ns2="local" id="64497"><DrugName>AAV-retinoschisin gene therapy (X-linked retinoschisis), AGTC/ Biogen</DrugName><DrugSynonyms><Name><Value>AAV-retinoschisin gene therapy (X-linked retinoschisis), Applied Genetic Technologies</Value></Name><Name><Value>XLRS gene therapy, Applied Genetic Technologies</Value></Name><Name><Value>X-linked retinoschisis gene therapy,  Applied Genetic Technologies</Value></Name><Name><Value>AAV-RS1 gene therapy (X-linked retinoschisis), Applied Genetic Technologies</Value></Name><Name><Value>rAAV-2tYF-CB-hRS1</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>AAV-retinoschisin gene therapy (X-linked retinoschisis), AGTC/ Biogen</Value></Name><Name><Value>BIIB-087</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="30577">AGTC</CompanyOriginator><CompaniesPrimary><Company id="30577">AGTC</Company></CompaniesPrimary><CompaniesSecondary><Company id="1005244">Biogen Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1005244" type="Company"><TargetEntity id="4295906748" type="organizationId">Biogen Inc</TargetEntity></SourceEntity><SourceEntity id="30577" type="Company"><TargetEntity id="4296993090" type="organizationId">Applied Genetic Technologies Corp</TargetEntity></SourceEntity><SourceEntity id="3238" type="ciIndication"><TargetEntity id="10061492" type="MEDDRA"></TargetEntity><TargetEntity id="D041441" type="MeSH"></TargetEntity><TargetEntity id="-1030195521" type="omicsDisease"></TargetEntity><TargetEntity id="5729" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C2">Phase 2 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="3238">Retinoschisis</Indication></IndicationsPrimary><ActionsPrimary><Action id="63382">RS1 gene stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="4781">Adeno-associated virus based gene therapy</Action><Action id="15128">Ophthalmological agent</Action></ActionsSecondary><Technologies><Technology id="62">Virus recombinant</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>S1</Code><Name>OPHTHALMOLOGICALS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-29T07:06:26.000Z</LastModificationDate><ChangeDateLast>2019-03-12T00:00:00.000Z</ChangeDateLast><AddedDate>2009-09-30T11:04:13.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="30577" linkType="Company"&gt;AGTC&lt;/ulink&gt; (previously Applied Genetic Technologies) is developing rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus (AAV)-vector expressing human retinoschisin (RS1)  gene for the potential treatment of X-linked retinoschisis (XLRS)  [&lt;ulink linkID="1005294" linkType="Reference"&gt;1005294&lt;/ulink&gt;], [&lt;ulink linkID="1045886" linkType="Reference"&gt;1045886&lt;/ulink&gt;], [&lt;ulink linkID="1383024" linkType="Reference"&gt;1383024&lt;/ulink&gt;], [&lt;ulink linkID="1590429" linkType="Reference"&gt;1590429&lt;/ulink&gt;], [&lt;ulink linkID="1675069" linkType="Reference"&gt;1675069&lt;/ulink&gt;].  In June 2015, a phase I/II study  was  initiated in the US for  retinoschisis [&lt;ulink linkID="1654131" linkType="Reference"&gt;1654131&lt;/ulink&gt;]; in September 2018, topline interim six-month data were expected by the end of  2018 and primary analysis of the full 12-month active trial data    by June 2019 [&lt;ulink linkID="2071073" linkType="Reference"&gt;2071073&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Licensee Biogen was previously developing the drug (as BIIB-087) for the potential  treatment of XLRS. In March 2019, Biogen terminated the collaboration agreement with AGTC [&lt;ulink linkID="2103793" linkType="Reference"&gt;2103793&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In February 2013, the COMP of the EMA adopted a positive opinion recommending the product for Orphan status for the treatment of XLRS [&lt;ulink linkID="1383024" linkType="Reference"&gt;1383024&lt;/ulink&gt;]; in March 2013, orphan status was granted [&lt;ulink linkID="1411042" linkType="Reference"&gt;1411042&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In September 2014,  the company planned to file IND, initiate phase I/II 	trials in late 2014 and initial clinical data were expected in the mid-2015 [&lt;ulink linkID="1590429" linkType="Reference"&gt;1590429&lt;/ulink&gt;]. In March 2015, an IND was filed with the US FDA and at that time, a phase I/II trial was expected to start in the second quarter of 2015  with  initial data expected in the second half of 2015 [&lt;ulink linkID="1640237" linkType="Reference"&gt;1640237&lt;/ulink&gt;]. In April 2015, an open-label, single group assignment, multi-site, phase I/II study (&lt;ulink linkID="227188" linkType="Protocol"&gt;NCT02416622&lt;/ulink&gt;; AGTC-RS1-001) was planned to be initiated in the US, in May 2015, to assess the safety and efficacy of the program in patients (expected n = 27) with x-linked retinoschisis. At that time, the study was expected to complete in December 2020; in June 2015, the trial was initiated [&lt;ulink linkID="1654131" linkType="Reference"&gt;1654131&lt;/ulink&gt;]. In August 2015, the trial reached a patient enrollment milestone [&lt;ulink linkID="1689711" linkType="Reference"&gt;1689711&lt;/ulink&gt;]. In May 2016, enrollment  was ongoing and interim data was expected  in   2016 [&lt;ulink linkID="1760509" linkType="Reference"&gt;1760509&lt;/ulink&gt;]. In Feburary 2017, data from the  the dose escalation phase were expected in in mid-2017 [&lt;ulink linkID="1899060" linkType="Reference"&gt;1899060&lt;/ulink&gt;]. By March 2017, enrollment in the dose escalation portion  had been completed. In May 2017, 	enrollment in the expansion group of the trial was initiated. At that time,  safety and  efficacy data from the first 12 patients  were expected in summer 2017  [&lt;ulink linkID="1926525" linkType="Reference"&gt;1926525&lt;/ulink&gt;]. In June 2017, top-line safety data from the first 12 subjects enrolled in the low, middle and high dose groups in the dose escalation portion were presented at the Macula Society Annual Meeting in Singapore. Data demonstrated that the therapy was generally well tolerated and demonstrated a good safety profile across treatment groups. Based on review by the Data Safety and Monitoring Committee, enrollment was continued at the highest dose in the expansion group; at that time, the company was planning to report additional updates with respect to safety, potential efficacy and biologic activity endpoints [&lt;ulink linkID="1936089" linkType="Reference"&gt;1936089&lt;/ulink&gt;]. By September 2017, a total of 17 adults and one child had been enrolled in the trial across all groups; at that time, enrollment of expansion group was expected to be completed by the first quarter of 2018 [&lt;ulink linkID="1961971" linkType="Reference"&gt;1961971&lt;/ulink&gt;]. By February 2018, 22 patients had been enrolled. At that time, available data showed  rAAV2tYF-CB-hRS1 to be generally safe and well tolerated [&lt;ulink linkID="2004191" linkType="Reference"&gt;2004191&lt;/ulink&gt;]. In April 2018, enrollment was completed in the trial. At that time, topline data from the trial were expected in the fourth quarter of 2018 [&lt;ulink linkID="2020952" linkType="Reference"&gt;2020952&lt;/ulink&gt;]. In September 2018, topline interim six-month data were expected by the end of  2018 with primary analysis of the full 12-month active trial data   by June 2019. At that time, based on the interim safety data in middle dose group, the company  planned to expand the trial with five pediatric patients at  high dose  [&lt;ulink linkID="2071073" linkType="Reference"&gt;2071073&lt;/ulink&gt;]. In December 2018, topline interim six-month data were reported. The drug was found to be safe and well tolerated with no   study discontinuations and   dose-related toxicities. Signs of clinical activity were not observed  for 6 months [&lt;ulink linkID="2103793" linkType="Reference"&gt;2103793&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2015, preclinical data were presented at the 18th ASGCT annual Meeting in New Orleans, LA.  In male cynomologus macaques, intravitreal administration of  rAAV2tYF-CB-hRS1   led to a dose-related anterior and posterior segment inflammatory response which improved over time [&lt;ulink linkID="1656898" linkType="Reference"&gt;1656898&lt;/ulink&gt;].  Further preclinical data were also presented at the same conference showing that intravitreal administration of rAAV2tYF-CB-hRS1 (1 or 4 x 10(12) vector genome/ml) did not show any effect on food consumption, body weight or mortality and was well tolerated  in male retinoschisin-deficient mice [&lt;ulink linkID="1657394" linkType="Reference"&gt;1657394&lt;/ulink&gt;], [&lt;ulink linkID="1660974" linkType="Reference"&gt;1660974&lt;/ulink&gt;]; in September 2015, the data were published [&lt;ulink linkID="1699425" linkType="Reference"&gt;1699425&lt;/ulink&gt;], [&lt;ulink linkID="1699348" linkType="Reference"&gt;1699348&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2015, preclinical data were presented at the 54th Society of Toxicology Annual Meeting in San Diego, CA. In cynomolgus macaques, treatment with single intravitreal injections of rAAV2tYF-CB-hRS1 (4 x 10(9), 4 x 10(10) or 4 x 10(11) vg/eye in a volume of 100 microl) in the right eye was well tolerated with no dose limiting toxicity [&lt;ulink linkID="1651706" linkType="Reference"&gt;1651706&lt;/ulink&gt;];  in September 2015, the data were published [&lt;ulink linkID="1699434" linkType="Reference"&gt;1699434&lt;/ulink&gt;], [&lt;ulink linkID="1699348" linkType="Reference"&gt;1699348&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2014, preclinical data were presented at the CHI Targeting Ocular Disorder conference in Boston, MA. A single dose  in a knockout mouse model showed an electrophysiological response. In a canine model of X-linked retinoschisis, subretinal delivery prevented photoreceptor degeneration. At this time primate studies were being designed [&lt;ulink linkID="1602389" linkType="Reference"&gt;1602389&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2011, the company received funding for a preclinical study evaluating the therapy's safety and efficacy [&lt;ulink linkID="1224704" linkType="Reference"&gt;1224704&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2009, gene therapy in mouse models of XLRS had been shown to result  in progressive and long-term improvement in retinal function and prevention of retinal cell degeneration [&lt;ulink linkID="1005294" linkType="Reference"&gt;1005294&lt;/ulink&gt;], [&lt;ulink linkID="1022204" linkType="Reference"&gt;1022204&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="30577">AGTC</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3238">Retinoschisis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2015-06-05T00:00:00.000Z</StatusDate><Source id="1654131" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="30577">AGTC</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3238">Retinoschisis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-02-05T00:00:00.000Z</StatusDate><Source id="1383024" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1005244">Biogen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3238">Retinoschisis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2019-03-08T00:00:00.000Z</StatusDate><Source id="2103793" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="30577">AGTC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3238">Retinoschisis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2009-05-01T00:00:00.000Z</StatusDate><Source id="1005294" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1005244">Biogen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3238">Retinoschisis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2015-07-02T00:00:00.000Z</StatusDate><Source id="1675069" type="PR"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="30577">AGTC</OwnerCompany><Country id="US">US</Country><Indication id="3238">Retinoschisis</Indication><AwardedIndication>Treatment of X-linked retinoschisis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2015-11-16T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="30577">AGTC</OwnerCompany><Country id="EU">EU</Country><Indication id="3238">Retinoschisis</Indication><AwardedIndication>Treatment of X-linked juvenile retinoschisis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-03-12T00:00:00.000Z</MileStoneDate><Source id="1411042" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="30577">AGTC</OwnerCompany><Country id="EU">EU</Country><Indication id="3238">Retinoschisis</Indication><AwardedIndication>Treatment of X-linked juvenile retinoschisis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2013-02-06T00:00:00.000Z</MileStoneDate><Source id="1383024" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="30577">AGTC</OwnerCompany><Country id="US">US</Country><Indication id="3238">Retinoschisis</Indication><AwardedIndication>Treatment of X-linked juvenile retinoschisis (XLRS).</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.opportunitymonitor.contract.service.ls.thomsonreuters.com/">2007-05-21T00:00:00.000Z</MileStoneDate><Source id="1383024" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="GTGT-11207"><Name>RS1 gene</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1005244">Biogen Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1059674">Foundation Fighting Blindness</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20575">University of Florida</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="22708">Oregon Health Sciences University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="30577">AGTC</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>5</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="3">Drug - Early Research/Development</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="8">Technology - Delivery/Formulation</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="126822" title="AGTC and NNRI to jointly research treatments for XLRS and achromatopsia using AAV delivery system "></Deal><Deal id="136388" title="Foundation Fighting Blindness to fund AGTC's preclinical development of X-linked retinoschisis gene therapy"></Deal><Deal id="136391" title="OHSU to collaborate with AGTC for the development of X-linked retinoschisis gene therapy"></Deal><Deal id="136393" title="University of Florida to collaborate with AGTC for the development of X-linked retinoschisis gene therapy"></Deal><Deal id="155202" title="Biogen to develop AGTC's gene-based therapies for orphan retinal diseases worldwide         "></Deal></Deals><PatentFamilies><PatentFamily id="1087352" number="WO-2009097129" title="Recombinant virus production using mammalian cells in suspension"></PatentFamily><PatentFamily id="3610523" number="WO-2017070491" title="Ophthalmic formulations"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Biogen Inc" id="1005244"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="AGTC" id="30577"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.opportunitymonitor.v1.DrugRecordOutput>